CGRP vs GLP-2

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Strengthens tight junctions and reduces intestinal permeability.

GLP-2 (glucagon-like peptide-2) is a 33-amino-acid endogenous proglucagon-derived peptide secreted by intestinal L-cells in response to nutrient ingestion, functioning as a trophic and protective hormone for the intestinal epithelium with roles in mucosal growth, barrier integrity, and nutrient absorption. GLP-2 signals through a specific receptor (GLP-2R) expressed on intestinal subepithelial myofibroblasts and enteric neurons, promoting enterocyte proliferation while inhibiting apoptosis, reducing intestinal permeability, and modulating gut motility to collectively support intestinal adaptation and absorptive capacity. Clinical evidence for GLP-2 pathway activity is established through teduglutide (Gattex/Revestive), a DPP-IV-resistant GLP-2 analog approved by the FDA in 2012 for short bowel syndrome-associated intestinal failure; Phase 3 trials and long-term follow-up studies demonstrated significant reductions in parenteral nutrition requirements, validating GLP-2 receptor agonism as a viable therapeutic approach. Native GLP-2 itself is not used therapeutically due to a plasma half-life of approximately 7 minutes from rapid DPP-IV degradation; clinical application is exclusively through the stabilized analog teduglutide, which requires a prescription and is indicated specifically for short bowel syndrome — a rare gastrointestinal condition — rather than general wellness or off-label intestinal support.